Treatment stratification by PET/CT has improved outcome and reduced treatment toxicity in Hodgkin Lymphoma. Recently, results of the GHSG HD18 trial were presented at EHA 2017. In this study, treatment stratification by PET/CT allowed reducing treatment duration to 4 cycles in most advanced stage patients with excellent efficacy. In the future, DNA, RNA or protein based biomarkers might play a similar role by allowing stratification of patients into biological risk groups and making measurement of minimal residual disease possible. Current technological advances increase the sensitivity of liquid biopsies to detect genetic abnormalities in many diseases. We are excited to see how these technologies will in uence the treatment of Hodgkin Lymphoma in the future.

The clinical relevance of some biomarkers such as TARC or specific microRNAs needs to be established. In addition, new technologies allow the evaluation of new biomarkers. We look forward to see more data in the near future in this exciting area.